Skip to main content

Table 4 Multivariate analysis of the inflammation-based cumulative prognostic score (ICPS) and IPI risk factors

From: An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era

Characteristic

OS

PFS

P-value

HR (95% Cl)

P-value

HR (95% Cl)

Age(>60y)

<0.001

2.493 (1.657–3.749)

0.250

1.228(0.865–1.745)

Ann Arbor stage(III,IV)

0.533

1.185(0.695–2.022)

0.295

1.254(0.821–1.914)

LDH(>245 U/L)

0.042

1.690(1.020–2.800)

0.018

1.642(1.087–2.479)

ECOG PS(≥2)

0.411

1.230(0.751–2.012)

0.022

1.579(1.069–2.330)

Extranodal sites(>1)

0.013

1.803(1.134–2.868)

0.187

1.305(0.879–1.937)

ICPS ≥ 2

0.001

2.476 (1.483–4.136)

0.019

1.611(1.080–2.404)

  1. Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard Ratio, 95% Cl, 95% confidence limits, LDH Lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, IPI International Prognostic Index, Hi High-intermediate, H High, ICPS Inflammation-based cumulative prognostic score
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us